KYAN Technologies
KYAN Technologies uses a small set of live-cell experiments and its own AI to rank more than 1,500 personalised drug combinations for a patient's cancer.
Overview
KYAN Technologies, based in Singapore with US operations, markets Optim.AI, a functional precision medicine platform that tests a patient's live cancer cells against drugs and uses its algorithm to evaluate and rank over 1,500 personalised combinations. Physician-ordered.
Similar pages
not linked directly; found by shared links- CompanyFirst Ascent Biomedical
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyStoreMyTumor
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyTravera
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- Company2cureX
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyCure-First
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanySageMedic
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanySpeciCare
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyCanCertain
Shares Functional (ex vivo) drug testing and the tag fcct-directory.